Boston Scientific is acquiring SoniVie, the developer of the catheter-based Tivus intravascular ultrasound system. With a ...

Boston Scientific recently announced it entered into a definitive agreement to acquire SoniVie Ltd. According to the press release, SoniVie is ...

An investigational technology, the TIVUS system is designed to denervate nerves surrounding blood vessels to treat a variety of hypertensive disorders, including renal artery denervation (RDN ...

Boston Scientific, Inc. BSX has signed a definitive agreement to acquire SoniVie Ltd., a privately held medical device company that developed the TIVUS Intravascular Ultrasound System.

TEL AVIV, Israel, July 13, 2022 /PRNewswire/ -- SoniVie, an Israeli company developing a novel proprietary Therapeutic Intra-Vascular Ultrasound (TIVUS â„¢) System to treat a variety of ...

Tivus is designed to denervate nerves surrounding blood vessels to treat a variety of hypertensive disorders, including renal artery denervation for hypertension, it added. As a strategic investor ...

March 3, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire SoniVie Ltd., a privately held medical device company that ...

An investigational technology, the TIVUS system is designed to denervate nerves surrounding blood vessels to treat a variety of hypertensive disorders, including renal artery denervation (RDN ...